

# Andrew L. Coveler, M.D.

October 12, 2017

825 Eastlake Avenue East  
UW Box 358081 G4-830  
Seattle, Washington 98109  
Tel: 206-606-7509 Fax: 206-606-2042  
acoveler@uw.edu

---

## PERSONAL

September 1976      Born

---

## EDUCATION

Sep 1995 – Jun 1998      **Bachelor of Arts in Biology, Magna Cum Laude**  
Northwestern University, College of Arts and Sciences, Evanston, Illinois

Aug 1998 – May 2002      **Doctor of Medicine**  
Northwestern University, Feinberg School of Medicine, Chicago, Illinois

---

## POSTGRADUATE TRAINING

Jun 2002 – Jun 2003      **Internship**  
Baylor College of Medicine Affiliated Hospitals, Houston, Texas

Jul 2003 – Jun 2005      **Internal Medicine Residency, Traditional Track**  
University of Washington Affiliated Hospitals, Seattle, Washington

Jul 2005 – Jun 2007      **Senior Fellow, Research Fellowship**  
Center for Translational Medicine in Women's Health  
The Tumor Vaccine Group, University of Washington, Seattle, Washington

Jul 2007 – Jun 2010      **Hematology-Oncology Fellowship**  
Fred Hutchinson Cancer Research Center / University of Washington, Seattle, WA

---

## FACULTY POSITIONS HELD

Jul 2010 – Sep 2011      **Acting Instructor**  
Division of Oncology, Department of Medicine  
University of Washington School of Medicine

Jul 2010 – Present      **Member**  
The Tumor Vaccine Group, University of Washington, Seattle, Washington

Oct 2011 – Jun 2017      **Assistant Professor**  
Division of Oncology, Department of Medicine  
University of Washington School of Medicine

Oct 2011 – Jun 2017      **Assistant Member, Clinical Research Division**  
Fred Hutchinson Cancer Research Center

Jul 2017 – Present      **Associate Professor**  
Division of Oncology, Department of Medicine  
University of Washington School of Medicine

Jul 2017 – Present      **Associate Member, Clinical Research Division**  
Fred Hutchinson Cancer Research Center

---

## HOSPITAL POSITIONS HELD

Jul 2005 – Dec 2009      **Adult Hospitalist, Locums Swedish Physicians Division**  
Swedish Medical Center, Seattle, Washington

# Andrew L. Coveler, M.D.

---

## HOSPITAL POSITIONS HELD CONTD.

Jul 2010 – Present	<b>Gastrointestinal Oncology, Attending Physician</b> Seattle Cancer Care Alliance, Seattle, Washington
Jul 2010 – Present	<b>Attending Physician</b> University of Washington Medical Center, Seattle, Washington
Sep 2015 – Present	<b>Director, Pancreas Cancer Specialty Clinic</b> Seattle Cancer Care Alliance

---

## HONORS & AWARDS

### *Undergraduate*

1995 – 1998	Robert C. Byrd Scholarship
1998	Phi Beta Kappa Honors Society

### *Medical School*

1995 – 2002	Acceptance into Northwestern University's Honors Program in Medical Education
2001	Clinical Honors in Obstetrics and Gynecology, 2001

---

## BOARD CERTIFICATIONS

Aug 2005 – Dec 2015	American Board of Internal Medicine, Internal Medicine
Nov 2010 – Dec 2020	American Board of Internal Medicine, Medical Oncology
Eligible	American Board of Internal Medicine, Hematology

---

## LICENSES TO PRACTICE

Jun 2002 – Aug 2003	State of Texas, BP10007051
Oct 2006 – Present	National Provider Identifier (NPI), 1669535670
Jul 2006 – Present	State of Washington, MD00045299
Jul 2008– Present	Drug Enforcement Agency

---

## ORGANIZATIONS & PROFESSIONAL ACTIVITIES

1998 – 2002	American Medical Student Association (AMSA)
2006 – Present	International Society for Biological Therapy of Cancer (iSBT) / Society for the Immunotherapy of Cancer (SITC)
2008 – Present	American Society of Clinical Oncology (ASCO)

---

## TEACHING RESPONSIBILITIES & ACTIVITIES

1999 – 2000	<i>Site Coordinator and Organizer, Patient Perspectives, Northwestern University</i>
1998 – 2000	<i>President 1999-2000, Member, Don't Choke on Smoke</i>
2000	<i>Teaching Assistant, Physical Exam Skills Unit</i>
Sep 2003	<i>Presentation, Chief of Medicine Conference, Papillary Muscle Rupture</i>
Nov 2003, Sep 2004	<i>Presentation, Mortality and Morbidity Case Review</i>

# Andrew L. Coveler, M.D.

---

## TEACHING RESPONSIBILITIES & ACTIVITIES CONTD.

Dec 2004	<i>Presentation</i> , Resident Teaching Conference, Ovarian Cancer
Oct 2007	<i>Presentation</i> , VA Grand Rounds, Tumor Immunotherapy
Jun 10, 2008	<i>Presentation</i> , Chief of Medicine Rounds, Tumor Lysis Syndrome
Aug 19, 2008	<i>Presentation</i> , Oncology Journal Club, Neoadjuvant Therapy for Pancreatic Cancer
Feb 26, 2009	<i>Presentation</i> , Oncology Journal Club, Testicular Cancer
Winter 2010	<i>Small Group Leader</i> , UW School Of Medicine, HuBio 552
Apr 2012 – Present	<i>Attending</i> , Solid Tumor Continuity Clinic, Seattle Cancer Care Alliance
May 2012	<i>PCSC (SCCA) Outreach</i> , in Tri Cities, Pancreas Cancer
Sep 2012	<i>Presentation</i> , UW/FHCRC/SCCA Comprehensive Oncology Review, Pathogenesis and Clinical Management of Pancreatic Cancer
Sep 2012	<i>Presentation</i> , UW/FHCRC/SCCA Comprehensive Oncology Review, Tumors Associated with Endocrine
Oct 2012	<i>Faculty Discussant</i> , Chief of Medicine Conference, Pseudomyxoma Peritonei, UW
Oct 2012	<i>Lecture</i> , Hematology/Oncology Fellows Lecture series, Colorectal Cancer
Dec 2012	<i>Faculty Discussant</i> , Hematology-Oncology Fellows' Solid Tumor Conference
Sep 2013	<i>Presentation</i> , UW/FHCRC/SCCA Comprehensive Oncology Review, Tumors Associated with Endocrine
Oct 2013	<i>Lecture</i> , GI Fellows Conference, Pancreas Cancer
Dec 2013	<i>SCCA Network Outreach</i> , at Bozeman Deaconess, Pancreas Cancer
Dec 2013	<i>Lecture</i> , Hematology/Oncology Fellows Lecture series, Colorectal Cancer
Mar 2014	<i>Lecture</i> , Radiology Imaging Clinical Lecture, Pancreas Cancer
Aug 2014	<i>Lecture</i> , Hematology/Oncology Fellows Lecture series, Colorectal Cancer
Sep 2014	<i>Presentation</i> , UW/FHCRC/SCCA Comprehensive Oncology Review, Tumors Associated with Endocrine
Sep 2014	<i>Presentation</i> , UW/FHCRC/SCCA Comprehensive Oncology Review, Anal Cancer
Sep 2014 – Jun 2015	Teaching Scholars Program, University of Washington
Mar 2015	<i>Lecture</i> , Radiology Imaging Clinical Lecture, Pancreas Cancer
Mar 2015	<i>Faculty Discussant</i> , Solid Tumor Conference, Gallbladder Cancer – a review with a twist.
May 2015	<i>Lecture</i> , Resident Core Teaching Conference, GI Malignancies with Emphasis on Colon Cancer.
Sep 2015	<i>Lecture</i> , Hematology/Oncology Fellows Lecture series, Colorectal Cancer
Sep 2015	<i>Presentation</i> , UW/FHCRC/SCCA Comprehensive Oncology Review, Anal Cancer
Sep 2015	<i>Presentation</i> , UW/FHCRC/SCCA Comprehensive Oncology Review, Pancreas Cancer
Nov 2015	<i>Lecture</i> , Resident Core Teaching Conference, GI Malignancies with Emphasis on Colon Cancer.
Mar 2016	<i>Presentation</i> , Seattle Cancer Care Alliance GI Cancer Symposium, New Treatments in Metastatic Colorectal Cancer

# Andrew L. Coveler, M.D.

Jun 2016	<i>Lecture</i> , Radiology Imaging Clinical Lecture, Body Oncology, Pancreas Cancer
Aug 2016	<i>Lecture</i> , Resident Core Teaching Conference, GI Malignancies with Emphasis on Colon Cancer
Aug 2016	<i>Presentation</i> , Advances in Cancer Immunotherapy (SITC), Immunotherapy on the Horizon
Sep 2016	<i>Presentation</i> , Fred Hutch Grand Rounds, Resectable Pancreas Cancer What, When and Where
May 9, 2017	<i>Lecture</i> , Radiation Oncology, Pancreas Cancer 2017
July 13, 2017	<i>Presentation</i> , Cases from Kampala, Pancreatic Cancer, Uganda Cancer Institute (WebEx)
July 13, 2017	<i>Presentation</i> , SCCA Schwartz Center Rounds Panel "Miracle and Tragedy"

---

## EDITORIAL RESPONSIBILITIES

2016 – Present	Editorial Board, Clinical Therapeutics
----------------	--

---

## SPECIAL NATIONAL RESPONSIBILITIES

Jul 2009 – Present	<b>Chair</b> , University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Comprehensive Oncology Review
Sep 2015 – Present	<b>Co-Chair</b> , Seattle Cancer Care Alliance, Comprehensive Oncology Update - Hawaii
Apr 2016 – Present	<b>Co-Organizer</b> , Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI™)

---

## SPECIAL LOCAL RESPONSIBILITIES

1995 – 1996	<i>Secretary</i> , Residential College Board
1996 – 1997	<i>Treasurer</i> , Residential College Board
1998 – 2000	<i>Member</i> , "Patient Physician and Society" Curriculum Review
1998 – 2000	<i>Webmaster</i> , Northwestern University Medical Student Cancer Society
1998 – 2002	<i>Editor</i> , Northwestern University Medical School Information Plexus: infoPLEX
1999 – 2000	<i>Clinical Coordinator</i> , Northwestern University Medical Student Cancer Society
1999 – 2000	<i>Member</i> , Honors Program in Medical Education (HPME) Admissions Committee
2000 – 2002	<i>Member</i> , Clinical Curriculum Task Force: Surgery/Subspecialty Committee
2008 – 2009	<i>Health Reach Patient Portal Committee</i> , Seattle Cancer Care Alliance
Jul 2008 – Dec 2009	<i>Fellow Representative</i> , Fred Hutchinson Cancer Research Center
Dec 2011- Present	<i>GI physician representative</i> , GOCOT, SCCA
Jan 2012 – 2013	<i>Specialist</i> , Concurrent Chemoradiation Working Group, SCCA
May 2012 – 2013	<i>Specialist</i> , GI Chemo Order Process Improvement Working Group, SCCA
May 2012 – Present	<i>Member</i> , SCCA Pathway Committee for Pancreas, Colon and Rectal Cancer
Jul 2012 – Dec 2015	<i>Specialist</i> , Lower GI Working Group, SCCA
Mar 2015 – Dec 2015	<i>Member</i> , SCCA/Cerner Clinical Pathways Partnership
Apr 2014 – Present	<i>Member</i> , Date Safety Monitor Committee

# Andrew L. Coveler, M.D.

---

## SPECIAL LOCAL RESPONSIBILITIES CONTD.

Mar 2015 – Present	<i>Member</i> , Order Governance Committee
Jan 2016 – Present	<i>Member</i> , GI Oncology Leadership Committee
Jan 2017 – Present	<i>Member</i> , GCSF Reimbursement Project Committee, SCCA
Jan 2017 – Present	<i>Member</i> , Care Unit Evaluation Committee, SCCA
Jan 2017 – Present	<i>Member</i> , Building Expansion Project Committee, SCCA
Aug 2017 – Present	<i>Member</i> , Inpatient Oncology Workgroup, UWMC

---

## RESEARCH FUNDING

### Current Active Research

**Project:** A Pivotal Phase III Study to Evaluate Overall Survival using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients with Cachexia.

**Sponsor:** XBiotech USA, Inc.

**Dates:** 03/14/2014 – 12/18/2016

**Amount:** \$341,346

**Role:** PI, Industry Sponsored

**Project:** Memorial Sloan Kettering – A phase II multicenter randomized trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision.

**Sponsor:** Memorial Sloan Kettering

**Dates:** 02/01/2015 – 01/31/2016

**Amount:** \$15,000

**Role:** Local PI

**Project:** A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies

**Sponsor:** Seattle Genetics, Inc.

**Dates:** 03/25/2015 – 02/01/2020

**Amount:** \$872,971.00

**Role:** PI, Industry Sponsored

**Project:** A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer

**Sponsor:** AbGenomics BV, Taiwan Branch

**Dates:** 04/01/2017 – 03/31/2019

**Amount:** \$380,386.00

**Role:** PI, Industry Sponsored

# Andrew L. Coveler, M.D.

---

## RESEARCH FUNDING CONTD.

### Recently Completed Research

**Project:** A Randomized, Placebo-Controlled, Double-Blind Phase 2 study of mFOLFOX6 chemotherapy plus Ramucirumab drug product (IMC-1121B) versus mFOLFOX6 plus placebo for advanced adenocarcinoma of the esophagus, gastroesophageal junction, or stomach.

**Sponsor:** Lilly USA, LLC

**Date:** 02/28/2011 – 02/27/2015

**Amount:** \$438,172

**Role:** PI, Industry sponsored

**Project:** A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer

**Sponsor:** New Link Genetics

**Dates:** 03/11/2011 – 02/01/2017

**Amount:** \$72,402

**Role:** PI, Industry sponsored

**Project:** Clinical Investigation Plan STX 0206: Randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma.

**Sponsor:** Sirtex Technology Pty Ltd.

**Dates:** 08/31/2011 – 03/01/2016

**Amounts:** \$125,030

**Role:** PI, Industry sponsored

**Project:** A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

**Sponsor:** Lilly Research Laboratories

**Dates:** 09/08/2011 – 05/31/2015

**Amount:** \$221,054

**Role:** PI, Industry sponsored

**Project:** A Phase II/III multi-center randomized controlled study to compare the efficacy and safety of Gemcitabine alone vs. ON 01910.Na combined with Gemcitabine in patients with previously untreated metastatic pancreatic cancer.

**Sponsor:** Onconova Therapeutics, Inc.

**Dates:** 05/10/2012 – 03/31/2015

**Amount:** \$163,606

**Role:** PI, Industry sponsored

**Project:** A Phase 2 randomized double-blind placebo-controlled study to evaluate the efficacy and safety of GS-6624 combined with Folfiri as second line treatment for metastatic KRAS or BRAF mutant colorectal adenocarcinoma that has progressed following a first-line Oxaliplatin and Fluoropyrimidine-containing regimen.

**Sponsor:** Gilead Sciences, Inc.

**Dates:** 06/05/2012 – 03/31/2015

**Amount:** \$163,565

**Role:** PI, Industry sponsored

---

## RESEARCH FUNDING CONTD.

**Project:** A phase II multicenter open label randomized study evaluating the efficacy and safety of FOLFIRI and MEHD7945A versus FOLFIRI and Cetuximab in second line therapy for patients with KRAS wild-type metastatic colorectal cancer.

**Sponsor:** Genentech, Inc.

**Dates:** 03/01/2013 – 02/28/2015

**Amount:** \$1,252,657

**Role:** PI, Industry Sponsored

**Project:** Funds to be used for the conduct of the Neoadjuvant Pancreatic Trial – (A phase II study of induction chemotherapy, neoadjuvant chemoradiotherapy, surgical resection and adjuvant chemotherapy for patients with locally advanced, resectable pancreatic adenocarcinoma). – for patient enrollment, followup, and preparation for data analysis.

**Sponsor:** Seattle Cancer Care Alliance – Swim Across America Funds

**Dates:** 04/09/2013 – 12/30/2019

**Amount:** \$26,080

**Role:** PI, Gift Account

**Project:** A Phase III Study Of Chemotherapy With Or Without Hyperacute®-Pancreas (algenpantucel-L) Immunotherapy In Subjects With Borderline Resectable Or Locally Advanced Unresectable Pancreatic Cancer

**Sponsor:** New Link Genetics

**Dates:** 06/26/2013 – 05/31/2019

**Amount:** \$215,668

**Role:** PI, Industry sponsored

**Project:** An open-label expanded access study of TAS-102 in patients with metastatic colorectal cancer refractory to or failing standard chemotherapy.

**Sponsor:** Taiho Oncology, Inc.

**Dates:** 02/25/2015 – 12/31/2017

**Amount:** \$4,643

**Role:** PI, Industry sponsored

**Project:** International, multi-center, double-blind, randomized, phase III trial of Y90-Clivatuzumab Tetraxetan plus low-dose Gemcitabine vs. placebo plus low-dose Gemcitabine in patients with metastatic Stage IV pancreatic adenocarcinoma who received at least 2 prior treatments.

**Sponsor:** Immunomedics, Inc.

**Dates:** 06/18/2015 – 09/30/2017

**Amount:** \$340,993

**Role:** PI, Industry sponsored

---

## PUBLICATIONS

### *Manuscripts*

1. LA Venta, RE Hendrick, Y Adler, P DeLeon, PM Mengoni, AM Scharl, CE Comstock, L Hansen, N Kay, A **Coveler**, G Cutter. Rates and Causes of Disagreement in Interpretation of Full-Field Digital Mammography and Film-Screen Mammography in a Diagnostic Setting. *Am J Roentgenol*, 2001; 176(5):1241–8. [Original Work]
2. LG Salazar, **AL Coveler**, RE Swensen, TA Gooley, V Goodell, K Schiffman, ML Disis. Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu. *Clin Immunol*, 2007; 125(3):278-80. [Original Work]

---

## PUBLICATIONS CONTD.

### *Manuscripts*

3. V Goodell, J Waisman, LG Salazar, C de la Rosa, J Link, **AL Coveler**, JS Childs, PA Fintak, DM Higgins, ML Disis. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. *Mol Cancer Ther*, 2008; 7(3):449-54. [Original Work]
4. ML Disis, D Wallance, TA Gooley, Y Dang, M Slota, H Lu, **AL Coveler**, J Childs, D Higgins, P Fintak, C de la Rosa, K Tietje, J Link, J Waisman, LG Salazar. Concurrent Trastuzumab and HER-2/neu Specific Vaccination in Patients with Metastatic Breast Cancer. *J Clin Oncol*, 2009; 27(28):4685-92. [Original Work]
5. **AL Coveler**, V Goodell, DJ Webster, LG Salazar, PA Fintak, JS Childs, DM Higgins, ML Disis. Common Adjuvant Breast Cancer Therapies do not Inhibit Cancer Vaccine Induced T Cell Immunity. *Breast Cancer Res Treat*, 2009; 113(1):95-100. [Original Work]
6. **AL Coveler**, N Bates, ML Disis. Progress in the development of a therapeutic vaccine for breast cancer. *Breast Cancer: Targets and Therapy*, 2010; 2:25-36. [Review]
7. \*M Zhao, WC Nelson, B Wei, PG Schiro, BM Hakimi, ES Johnson, RK Anand, GS Gyurkey, LM White, SH Whiting, **AL Coveler**, DT Chiu. New Generation of Ensemble-Decision Aliquot Ranking Based on Simplified Microfluidic Components for Large-Capacity Trapping of Circulating Tumor Cells. *Anal Chem*, 2013;85(20):9671-7. [Original Work]
8. ML Disis, Y Dang, **AL Coveler**, E Marzbani, ZC Kou, JS Childs, P Fintak, DM Higgins, J Reichow, J Waisman, LG Salazar. HER-2/neu Vaccine-Primed Autologous T-cell Infusions For The Treatment of Advanced Stage HER-2/neu Expressing Cancers. *Cancer Immunol Immunother*, 2014;63(2):101-9. [Original Work]
9. SA Padia, SW Kwan, B Roudsari, WL Monsky, **A Coveler**, WP Harris. Supersselective Yttrium-90 Radioembolization for Hepatocellular Carcinoma Yields High Response Rates with Minimal Toxicity. *J Vasc Interv Radiol*, 2014;25(7):1067-73. [Original Work]
10. \*S Patel, S Chandrasekaran, GN Mann, S Chandrasekaran, FR Lucas, EY Kim, **AL Coveler**. Neoadjuvant therapy in borderline resectable pancreatic ductal adenocarcinoma: A single institution review. *Journal of Solid Tumors*, 2014 Dec 9;4(4):1-8. [Original Work]
11. M Konopleva, PF Thall, YC Arana, G Borthaku, **A Coveler**, C Bueso-Ramos, J Benito, S Konoplev, Y Gu, F Ravandi, E Jabbour, S Faderi, D Thomas, J Cortes, T Kadia, S Kornblau, N Daver, N Pemmaraju, GQ Nguyen, J Feliu, H Lu, C Wei, WR Wilson, TJ Melink, JC Gutheil, M Andreeff, EH Estey, H Kantarjian. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. *Haematologica*, 2015;100(7):927-34. [Original Work]
12. F Birzele, E Voss, A Nopora, K Honold, F Heil, S Lohmann, H Verheul, C Le Tourneau, JP Delor, C van Herpen, D Mahalingam, **AL Coveler**, V Meresse, S Weigand, V Runza, M Cannarile. CD44 isoform status predicts response to treatment with anti-CD44 antibody in cancer patients. *Clin Cancer Res*, 2015; 21(12):2753-62. [Original Work]
13. BH O'Neil, AJ Scott, WW Ma, SJ Cohen, L Leichman, DL Aisner, AR Menter, MA Tejani, JK Cho, J Granfortuna, **AL Coveler**, OO Olowokure, JC Baranda, M Cusnir, P Phillip, J Boles, R Nazemzadeh, M Rarick, DJ Cohen, J Radford, L Fehrenbacher, R Bajaj, V Bathini, P Fanta, J Berlin, AJ McRee, R Maguire, F Wilhelm, M Maniar, A Jimeno, CL Gomes, WA Messersmith. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. *Ann Oncol*, 2015;26(9):1923-9 [Original Work]
14. \*EG Chiorean, **AL Coveler**. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. *Drug Des Devel Ther*, 2015;9:3529-45. [Review]



---

## PUBLICATIONS CONTD.

### *Manuscripts*

15. KA McCormick, **AL Coveler**, GR Rossi, NN Vahanian, C Link, EG Chiorean. Pancreatic Cancer: Update on Immunotherapies and Algenpantucel-L. *Hum Vaccin Immunother*, 2016;12(3):536-75. [Review]
16. \***AL Coveler**, GR Rossi, NN Vahanian, C Link, EG Chiorean. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. *Immunotherapy*, 2016;8(2):117-25. [Review]
17. **AL Coveler**, P. Richard, S. Apisarnthanarax, EG Chiorean. Is there a best radiosensitizing agent in the treatment of locally advanced rectal cancer? *Current Colorectal Cancer Reports*, 2016;12(4):189-200.
18. \***AL Coveler**, AH Ko, DVT Catenacci, D Von Hoff, Carlos Becerra, NC Whiting, J Yang, B Wopin. A phase I clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancer. *Invest New Drugs*, 2016;34(3):319-28. [Original Work]
19. **AL Coveler**, JM Herman, DM Simeone, EG Chiorean. Localized Pancreatic Cancer: Multidisciplinary Management. *ASCO Education Book*, 2016;35:e217-26.
20. CW Menke-van der Houven van Oordt, C Gomez-Roca, C van Herpen, **AL Coveler**, D Mahalingam, HMW Verheul, WTA van der Graaf, R Christen, D Ruttinger, S Weigand, MA Cannarile, F Heil, M Brewster, AC Walz, TK Nayak, E Gauarin, V Meresse, C Le Tourneau. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44 expression solid tumors. *Oncotarget*, 2016;7(48):80046-58. [Original Work]
21. LG Salazar, H Lu, JL Reichow, JS Childs, **AL Coveler**, DM Higgins, J Waisman, KH Allison, Y Dang, ML Disis. Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial. *JAMA Oncol*, 2017;3(7):969-73. [Original Work]
22. KM Wong, KJ Horton, **AL Coveler**, SR Hingorani, WP Harris. Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20). *Curr Oncol Rep*, 2017;19(7):47. [Review]
23. X Jiang, YD Seo, JH Chang, **A Coveler**, EN Nigjeh, S Pan, F Jalikis, RS Yeung, IN Crispe, VG Pillarisetty. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. *OncImmunity*, 2017 May 25, Epub. [Original Work]

### *Book Chapters*

1. **AL Coveler** and ML Disis. Immunologic Biomarkers to Predict Vaccine Efficacy. *AACR Education Book*, 2009(1): 125.
2. **AL Coveler**, VG Oehler. Chronic Myelogenous Leukemia (CML). *Leukemia and Related Disorders Integrated Treatment Approaches*. New York. 2012, 97.
3. EG Chiorean, **AL Coveler**, J Grim, WM Grady. Targeted Therapies for Intestinal Tumors. *Intestinal Tumorigenesis*. Switzerland. 2015.

### *Published Books, Videos, Software, Etc*

1. None

### *Other Publications*

1. None

### *Submitted Manuscripts*

1. None

---

## PUBLICATIONS CONTD.

### Abstracts

1. V Goodell, J Waisman, LG Salazar, C de la Rosa, J Link, **AL Coveler**, DJ Webster, JS Childs, PA Fintak, DM Higgins, ML Disis. The level of HER-2/neu protein expression in primary breast cancer may impact the development of HER-2/neu specific endogenous immunity. *SABCS. Breast Cancer Research and Treatment*, Vol. 100, Suppl.1, December 2006.
2. LG Salazar, **A Coveler**, PA Fintak, D Higgins, JR Waisman, M Krug, ML Disis. Low doses of a plasmid DNA vaccine encoding the HER-2/neu intracellular domain effectively stimulate tumor specific immunity. *29th Annual SABCS. Breast Cancer Research and Treatment*, Vol. 100, Supplement 1, December 2006.
3. LG Salazar, **A Coveler**, PA Fintak, D Higgins, JR Waisman, M Krug, ML Disis. Low doses of a DNA plasmid based vaccine encoding the HER-2/neu (HER2) intracellular domain (ICD) effectively stimulate tumor specific immunity. *ASCI/AAP Joint Meeting 2007*.
4. LG Salazar, R Swesen, V Markle, **A Coveler**, B Royer, Y Dang, M Slota, J Childs, D Wallace, ML Disis. Phase I study of intraperitoneal (IP) denileukin difitox in patients with advanced ovarian cancer (OC). *Journal of Clinical Oncology 26*: 2008. (May 20 suppl; abstr 3036)
5. LG Salazar, D Wallace, P Mukherjee, D Higgins, J Childs, N Bates, **A Coveler**, ML Disis. Development of HER-2/neu (HER2)-specific T cell immunity in patients with HER2-positive inflammatory breast cancer (IBC) may impact prognosis. *International Inflammatory Breast Cancer Conference*, University of Texas M.D. Anderson Cancer Center, December 2008.
6. PA Fintak, DR Wallace, DM Higgins, JS Childs, **AL Coveler**, LG Salazar, J Link, J Waisman, ML Disis. Common Sources of Referral to Early Phase Clinical Trials for Breast and Ovarian Cancer in a Translational Research Setting. *San Antonio Breast Cancer Symposium*, December 2008.
7. LG Salazar, M Slota, D Wallace, D Higgins, **AL Coveler**, Y Dang, J Childs, N Bates, J Waisman, ML Disis. A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. *Journal of Clinical Oncology 27*:15s, 2009. (suppl; abstr 3054)
8. J Keller, J Childs, Y Dang, LG Salazar, D Higgins, N Bates, **A Coveler**, ML Disis. The impact of clinical parameters, in cancer patients refractory to standard therapy, on the feasibility of expanding tumor antigen specific T-cells ex vivo. *iSBTc*, 2009.
9. LG Salazar, M Slota, D Wallace, D Higgins, **AL Coveler**, Y Dang, J Childs, N Bates, J Waisman, ML Disis. A phase I study of a DNA plasmid based vaccine encoding the HER-2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. *Proceedings, American Society of Clinical Oncology*, 2009.
10. ML Disis, Y Dang, N Bates, D Higgins, J Childs, M Slota, **A Coveler**, E Jackson, J Waisman, L Salazar. Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Vaccine Given Concurrently with Trastuzumab in Patients with Newly Diagnosed Advanced Stage Breast Cancer. *San Antonio Breast Cancer Symposium*, 2009.
11. J Childs, LG Salazar, D Higgins, **A Coveler**, N Bates, D Wallace, B O'Byrne, ML Disis. Improving Adverse Event Collection in Early Phase Oncology Clinical Trials. *Society of Clinical Research Associates Annual Conference*, 2009.
12. ML Disis, LG Salazar, **AL Coveler**, J Waisman, D Higgins, J Childs, N Bates, Y Dang. Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 over expressing cancers who have received a HER2 vaccine. *American Society of Clinical Oncology Annual Meeting*, 2009.

---

## PUBLICATIONS CONTD.

### Abstract

13. D Wallace, ML Disis, **AL Coveler**, D Higgins, J Childs, N Bates, L Salazar, M Slota, Y Dang, J Waisman. Association of the level of HER2/neu (HER2) gene amplification in breast cancer and the magnitude of antigen specific T-cell immunity achieved after HER2 vaccination. *American Society of Clinical Oncology Annual Meeting, General Poster Session*, 2009.
14. LG Salazar, D Wallace, P Mukherjee, D Higgins, J Childs, N Bates, **AL Coveler**, ML Disis. Development of HER-2/neu (HER2) specific T cell immunity in patients with HER2+ inflammatory breast cancer (IBC) may impact prognosis. *Proceedings, American Society of Clinical Oncology*, 2009.
15. ML Disis, LG Salazar, **A Coveler**, J Waisman, D Higgins, J Childs, N Bates, Y Dang. Phase I study of infusion of HER-2/neu (HER2) specific T cells in patients with advanced stage HER2 overexpressing cancers who have received a HER2 vaccine. *Proceedings, American Society of Clinical Oncology*, 2009.
16. LG Salazar, D Higgins, J Childs, N Bates, Y Dang, M Slota, **AL Coveler**, JR Waisman, ML Disis. Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer. *San Antonio Breast Cancer Symposium*, December 2009.
17. ML Disis, LG Salazar, **A Coveler**, J Waisman, D Higgins, J Childs, N Bates, Y Dang. Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine. *Journal of Clinical Oncology* 27:15s, 2009. (suppl; abstr 3000)
18. LG Salazar, D Wallace, P Mukherjee, D Higgins, J Childs, N Bates, **AL Coveler**, ML Disis. HER2/neu (HER2) specific T-cell immunity in patients with HER2+ inflammatory breast cancer (IBC) and prognosis. *Journal of Clinical Oncology* 27:15s, 2009. (suppl; abstr 3057)
19. E Broussard, **A Coveler**, M Slota, E Jackson, N Bates, D Higgins, J Childs, Y Yang, M Disis. Identification and characterization of colon cancer-associated antigens. *Cancer Prevention Research*, December 2010
20. M Konopleva, G Borthakur, P Thall, **A Coveler**, F Ravandi, E Jabbour, H Nguyen, J Benito, Y Gu, W Wilson, T Melink, H Kantarjian, J Gutheil, E Estey. Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient Specific Adaptive Dose Selection. *53rd ASH Annual Meeting and Exposition*. December 2011
21. SL Parker, DM Higgins, J Childs, Y Dang, K Guthrie, M Disis, L Salazar, **A Coveler**. Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming with a HER2 Peptide-Based Vaccine in Patients with Stage IV Breast Cancer. *San Antonio Breast Cancer Symposium*, December 2011
22. E Broussard, **A Coveler**, S Whiting, R Kim, L Rastetter, E Gad, M Slota, G Gyurkey, J Childs, D Higgins, M Disis. Characterization of Colon Cancer-Associated Antigens Which Would Be Key Therapeutic Targets in the Prevention of Disease Relapse or Progression. *ASCO Gastrointestinal Cancers Symposium*, 2012.
23. **AL Coveler**, DD Von Hoff, AH Ko, NC Whiting, B Zhao, BM Wolpin. A Phase 1 Study of ASG-5ME, a Novel Antibody-Drug Conjugate, in Pancreatic Ductal Adenocarcinoma. *ASCO Gastrointestinal Cancers Symposium*, January 2013.
24. S Chandrasekaran, **AL Coveler**, S Chandrasekaran, FR Lucas, S. Patel. Neoadjuvant Therapy for Achieving Margin Negative Resection in Borderline Resectable Pancreatic Ductal Adenocarcinoma. *ASTRO Annual Meeting*, September 2013
25. LG Salazar, H Lu, H Gray, D Higgins, J Childs, Y Dang, M Slota, S Parker, J Reichow, **AL Coveler**, ML Disis. Final results of a phase II study of topical imiquimod and weekly abraxane in patients with breast cancer cutaneous metastases. *San Antonio Breast Cancer Symposium*, December 2013.

---

## PUBLICATIONS CONTD.

### *Abstract*

26. K McCormick, SH Whiting, G Gyurkey, WJ Koh, M Sinanan, **AL Coveler**. Long-term survival of patients receiving multimodality neoadjuvant therapy for resectable or borderline resectable pancreatic ductal adenocarcinoma. *ASCO Gastrointestinal Cancers Symposium*, January 2014.
27. **AL Coveler**, VG Pillarisetty, G Gyurkey, WJ Koh, M Upton, C Cuevas, T Gooley, EG Chiorean, V Shankaran, WP Harris, JO Park, GN Mann, DR Byrd, S Balas, SH Whiting. A phase II study of perioperative therapy for patients with resectable and borderline resectable pancreatic adenocarcinoma. *ASCO*, June 2014
28. ML Disis, **AL Coveler**, D Higgins, LA D'Amico, C Morishima, JRoss Waisman, J Reichow, J Childs, Y Dang, LG Salazar, E Marzbani. Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2+ breast cancer. *ASCO*, June 2014
29. ML Disis, **AL Coveler**, D Higgins, P Fintak, JR Waisman, J Reichow, M Slota, J Childs, Y Dang, LG Salazar. A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer. *ASCO*, June 2014
30. AJ Scott, BH O'Neil, C Gomes, JC Baranda, SJ Cohen, MA Tejani, RT Maguire, F Wilhelm, M Maniar, DJI Cohen, WW Ma, D Aisner, JK. Cho, OO Olowokure, **AL Coveler**, AR Menter, P Rubin, M Cusnir, WA Messersmith. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. *ASCO Gastrointestinal Cancers Symposium*, January 2015.
31. **AL Coveler**, DC Smith, JE Grilley-Olson, TF Gajewski, S Goel, SJ Gardai, CL Law, G Means, T Manley, B Curti. SEA-CD40 is a CD40 agonist with early evidence of pharmacodynamic and antitumor activity: preliminary results from a phase I study in advanced solid malignancies. *Society for Immunotherapy of Cancer*, November 2016.
32. E Torti, JO Park, EG Chiorean, EY Kim, S Cohen, **AL Coveler**. Retrospective review of outcomes in patients (pts) with synchronous metastatic rectal cancer (mRC) receiving initial non-surgical management. *ASCO Gastrointestinal Cancer Symposium*, January 2017.
33. AE Chang, S Shahda, WP Harris, SA Cohen, **AL Coveler**, BH O'Neil, VK Gadi, R Hibbert, HH Lee, A Younger, KA McCormick, C Pritchard, MW Redman, EG Chiorean. Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreaticobiliary cancers. *ASCO Gastrointestinal Cancer Symposium*, January 2017.